Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/2/2026 | $113.00 | Outperform → Market Perform | Leerink Partners | |
| 1/21/2026 | $790.00 | Outperform → Strong Buy | Raymond James | |
| 1/16/2026 | $142.00 | Neutral → Buy | Goldman | |
| 1/15/2026 | $105.00 | Outperform | RBC Capital Mkts | |
| 1/14/2026 | $700.00 | Hold | Jefferies | |
| 1/14/2026 | $85.00 | Buy | Jefferies | |
| 1/8/2026 | Hold | Deutsche Bank | ||
| 1/8/2026 | Buy | Deutsche Bank |
4 - Victoria's Secret & Co. (0001856437) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4/A - Marvell Technology, Inc. (0001835632) (Issuer)
144 - BioNTech SE (0001776985) (Subject)
S-8 - Marvell Technology, Inc. (0001835632) (Filer)
8-K - Marvell Technology, Inc. (0001835632) (Filer)
REYNOLDSBURG, Ohio, Feb. 12, 2026 (GLOBE NEWSWIRE) -- In conjunction with the Victoria's Secret & Co. (NYSE:VSCO) fourth quarter 2025 earnings release, you are invited to listen to a live webcast of the conference call on Thursday, March 5th at 8:30 a.m. ET with Victoria's Secret & Co. executives. The earnings release and related financial information detailing the company's fourth quarter results are expected to be issued approximately one hour prior to the start of the live webcast. The earnings release and related financial information will be available on our website at victoriassecretandco.com/investors. What:Victoria's Secret & Co. Fourth Quarter 2025 Earnings Conference Call Webcast
Marvell Technology, Inc. (NASDAQ:MRVL), a leader in data infrastructure semiconductor solutions, today announced that it has completed its previously announced acquisition of XConn Technologies ("XConn"), a provider of advanced PCIe and CXL switching silicon. The acquisition expands Marvell's switching portfolio with XConn's PCIe and CXL products and strengthens Marvell's capabilities in scale-up connectivity for next-generation AI and cloud data center architectures. XConn's engineering team and technology will play a key role in advancing Marvell's UALink scale-up switching roadmap as AI systems evolve toward larger, multi-rack deployments. Expected Financial Impact Marvell expect
Unrestricted Power features a new proprietary fabric innovation and performance-led design to deliver an unmatched combination of support, mobility, and on-body feel The training assortment was developed with lululemon Ambassadors, including Lewis Hamilton & Kayla Jeter lululemon (NASDAQ:LULU) today unveiled Unrestricted Power™, a new innovation platform engineered for heavy lifts and demanding gym sessions. The assortment, which launches this morning in North America, is backed by thousands of hours of research and development, providing secure support without compromising comfort and mobility, enabling a distraction-free fit built to match every move. This press release features mult
4 - Elastic N.V. (0001707753) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00
Raymond James upgraded Ulta Beauty from Outperform to Strong Buy and set a new price target of $790.00
Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00
For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of
Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:
Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),
Delivered Net Sales of $1.472 Billion, a 9% Increase Versus Prior Year, Exceeding ExpectationsOperating Results and Earnings Exceed ExpectationsRaises Fiscal Year 2025 Net Sales, Operating Income and Earnings Guidance REYNOLDSBURG, Ohio, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Victoria's Secret & Co. ("VS&Co" or the "Company") (NYSE:VSCO) today reported financial results for the third quarter ended November 1, 2025. Hillary Super, VS&Co Chief Executive Officer, said, "We delivered a standout third quarter, with outperformance on net sales and earnings per share, exceeding the high-end of our guidance. Net sales increased 9% over last year, driven by strength across Victoria's Secret, PINK and
SC 13D/A - MARKETWISE, INC. (0001805651) (Subject)
SC 13G/A - Victoria's Secret & Co. (0001856437) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
REYNOLDSBURG, Ohio, Feb. 12, 2026 (GLOBE NEWSWIRE) -- In conjunction with the Victoria's Secret & Co. (NYSE:VSCO) fourth quarter 2025 earnings release, you are invited to listen to a live webcast of the conference call on Thursday, March 5th at 8:30 a.m. ET with Victoria's Secret & Co. executives. The earnings release and related financial information detailing the company's fourth quarter results are expected to be issued approximately one hour prior to the start of the live webcast. The earnings release and related financial information will be available on our website at victoriassecretandco.com/investors. What:Victoria's Secret & Co. Fourth Quarter 2025 Earnings Conference Call Webcast
Marvell Technology, Inc. (NASDAQ:MRVL), a leader in data infrastructure semiconductor solutions, today announced it will conduct a conference call following the release of its fourth fiscal quarter and fiscal year 2026 financial results on Thursday, March 5, 2026, at 1:45 p.m. Pacific Time. Conference Call Interested parties may join the live conference call without operator assistance at Call me™ (link will be active approximately 30 minutes before the call) to receive an instant automated callback. To join the call with operator assistance, please dial 1-877-407-8291 or 1-201-689-8345. The call will be webcast and can be accessed at the Marvell Investor Relations website at http://inv
WILMINGTON, Del., Feb. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its fourth quarter 2025 financial results after market on Thursday, February 19, 2026. The Company expects to hold its conference call to discuss its fourth quarter 2025 financial results at 8:00 a.m. Eastern Time on Friday, February 20, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of